Rational Approach to AIDS Drug Design Through Structural Biology
- 1 February 2002
- journal article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 53 (1) , 595-614
- https://doi.org/10.1146/annurev.med.53.052901.131947
Abstract
The discovery and development of more than a dozen drugs in the past 15 years for the treatment of AIDS offer an excellent example of progress in the field of rational drug design. At this time, the principal targets are reverse transcriptase and protease, enzymes encoded by the human immunodeficiency virus. The introduction of protease inhibitors, in particular, has drastically decreased the mortality and morbidity associated with AIDS. This review presents the methods used to develop such drugs and discusses the remaining problems, such as the rapid emergence of drug resistance.Keywords
This publication has 104 references indexed in Scilit:
- On the size of the active site in proteases. I. PapainPublished by Elsevier ,2005
- LopinavirDrugs, 2000
- Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases 1 1Edited by R. HuberJournal of Molecular Biology, 1998
- The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutantFEBS Letters, 1996
- Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical TrialsJournal of Biological Chemistry, 1996
- A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor designProtein Science, 1995
- Solution Structure of HIV-1 Protease-Allophenylnorstatine Derivative Inhibitor Complex Obtained from Molecular Dynamics Simulation.CHEMICAL & PHARMACEUTICAL BULLETIN, 1994
- STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASEAnnual Review of Biochemistry, 1993
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivativeBiochemical and Biophysical Research Communications, 1989